|
|
|
Day 1 - Monday 1st September 2008
Research Track
|
08:55 |
Advances in Tissue Engineering & Regenerative Medicine
Chair: Dr Fergus McKenzie, ITI Life Sciences |
|
09:00 |
Mobilization of Unique Populations of Haematopoietic Progenitor Cells in Response to Clinical Situations Associated with Liver Regeneration
Ursula Gehling, Head of Research Laboratory, University Hospital Hamburg |
|
09:30 |
Key Note Presentation
Stem Cells and the Heart - Wherer are We?
Magdi Yacoub, Professor, Imperial College |
|
10:00 |
A Chemical Approach to Stem Cell Biology
Sheng Ding, Professor, Scripps Research Institute
This presentation will discuss identifications and mechanistic characterizations of small molecules that control self-renewal, differentiation, and reprogramming of various stem/progenitor cells. |
|
10:30 |
Coffee and Networking in Main Exhibition Hall |
|
11:15 |
Embryonic Stem Cell-Derived Neurons as a Novel Cellular Model System to Study Neurodegenerative and Neuroregenerative Processes in Vitro
Miriam Bibel, Senior Researcher, Novartis Institute for BioMedical Research |
|
11:45 |
Stem Cells for Safer Medicines
Louise Leong, Science Director, Stem Cells for Safer Medicine
SC4SM was recently established as a public-private consortium to enhance the safety assessment of new medicines. The presentation will give an overview of its research priorities, longterm scientific strategy, and how the partnership works. |
|
12:15 |
Lunch and Poster Presentations |
|
14:00 |
Key Note Presentation
Therapeutic and Research Potential of Human Stem Cells
Stephen Minger, Professor, Kings College London
Progress in the fields of stem cell biology and regenerative medicine is accelerating rapidly. This talk with provide an overview of how different populations of human stem cells will and can be used in both a clinical and research setting. |
|
14:30 |
Key Note Presentation
Stem cells and drug discovery
Ian Wilmut, Centre for Regenerative Medicine, University of Edinburgh |
|
15:00
|
Maintaining the Epigenetic Stability of Human Pluripotent Cells
Lorraine Young, Professor, Wolfson Centre for Stem Cells
This presentation will focus on the scientific challenges required to be overcome before human embryonic stem cells and induced pluripotency cells can become consistent cell products, rather than research tools. Current progress will be highlighted. |
|
15:30 |
Coffee and Networking in Main Exhibition Hall |
|
16:15 |
Genetic Regulation of the Stem Cell Niche and the Outcome of Stem Cell Therapy in Blinding Ocular Surface Disease
Julie Daniels, Head of Department, UCL Institute of Ophthalmology
Corneal transparency and therefore vision is dependent upon the functionality of limbal epithelial stem cells (LESCs). The effect of haploinsufficiency of the eye development gene Pax6 on LESC functionality and the outcome of cultured LESC therapy in patients will be discussed |
|
16:45 |
Increased Endothelial Apoptosis and Impaired Endothelial Regeneration
Caroline Schmidt-Lucke, Director, Depertment for Cardiology, Charité
Cardiac persistence of the vasculotropic virus B19 is associated with andothelial dysfunction. The mechanisms leading to endothelial damage in vivo are unclear. Indeed, data of our study show, that persistence of B19 markedly increased endothelial cell apoptosis in patients with B19 and is associated with reduced functional capacity of progenitor cells. |
|
17:15 |
Challenges and Opportunities Facing Stem Cell Commercialisation
Cathy Prescott, Director, Biolatris Ltd |
|
17:45 |
miRNA Inhibitor and Mimic Screen Identifies Regulators of Human MSC
Stephanie Urschel, Senior Field Scientist, Thermo Fisher Scientific
Pluripotent adult human mesenchymal stem cells (hMSCs) are capable of differentiating into a variety of cell types. We will describe an RNAi-based screen to investigate the role of miRNAs in stem cell differentiation and to demonstrate application of RNAi tools in regenerative medicine and research. |
|
18:15 |
Drinks Reception |
Day 2 - Tuesday 2nd September 2008
Research Track
|
08:55 |
Chair: Stephen Minger, Professor, Kings College London |
|
09:00 |
Stem Cell Space in Research and Regenerative Medicine
Enal Razvi, Biotechnology Analyst, Select Biosciences
This presentation will present snapshots from Select Biosciences continual industry coverage of the stem cell spaces for life science research, drug discovery, and regenerative medicine. Data from our worldwide market analyses are presented and framed in the context of the market opportunities in these segments. |
|
09:30 |
Flow Cytometric Set up and Challenges with Respect to Stem Cells
Ian Dimmick, Flow Cytometry Manager , North East England Stem Cell Institute
Stem cells present unique challenges to anyone who wants to sort or analyse these cells. I will review the procedures we have in place to enable accurate and sensitive flow cytometry and sorting. |
|
10:00 |
Coffee and Networking in the Main Exhibition Hall |
|
11:15 |
Induction of Immunologic Tolerance and Gerontoprotector Effects of Embryonic Progenitor Cell Transplantation in Rats and Mice
Oleksandr Kukharchuk, Head Transplantologist, Minister of Health of Ukraine
Survival, reproductive function and response for allotransplantion of skin and spleen have been examined to check on the principle provisions of theory of stem space deterioration, as a basis of mammalians' aging, following administration of mega-doses of embryonic progenitor cells (EPC) to old male rats and mice. Administration of mega-doses of EPC induces central immunological tolerance and extends stem spaces that prolong old animals' life-span and restore their reproductive function. |
|
11:45 |
Cardiovascular Cell Therapy with Human Mesenchymal Stem Cells: New Molecules with Differentiating and Paracrine Logics
Carlo Ventura, Professor, University of Bologna
Hyaluronan mixed esters of butyric and retinoic acid (HBR) afforded cardiovascular commitment and paracrine secretion of trophic mediators in human mesenchymal stem cells. HBR-preconditioned cells remarkably rescued infarcted rat hearts, paving the way to novel approaches in cardiovascular cell therapy. |
|
12:15 |
Lunch and Poster Presentations |
|
13:55 |
Chair: Enal Razvi, Biotechnology Analyst, Select Biosciences |
|
14:00 |
Human Mesenchymal Stem Cells Accelerate the Healing of Skin and Increase Intestinal Recovery after Radiation Injury
Alain Chapel, Principal Investigator, Institute of Nuclear Safety |
|
14:30 |
Generation of Pluripotent Stem Cells from Adult Human Testis
Thomas Skutella, Director, University of Tuebingen |
|
15:00 |
Cancer Stem Cells: New Therapeutic Targets
Dominique Bonnet, Senior Group Leader, Cancer Research UK |
|
15:30 |
Coffee and Networking in Main Exhibition Hall |
|
16:15 |
Circulating Endothelial Progenitor Cells as Cellular Biomarkers in Vascular Disease
Mihail Hristov, Senior Group Leader, University Hospital Aachen |
|
16:45 |
Assay Strategies for the Identification of Small Molecule Modulators of Human Embryonic Stem Cells
Hakim Djaballah, Director HTS Core Facility, Memorial Sloan-Kettering Cancer Center
This group has successfully screened a chemical library and identified several modulators of human embryonic stem cells; some of which induced differentiation and others simply maintained the cells in an undifferentiated state. |
|
17:15 |
Pathogen Detection in Human Stem Cell Cultures Using Quantitative Real-Time PCR
Lyn Healy, Senior Stem Cell Biologist, UK Stem Cell Bank
Applied Biosystems have developed quantitative real-time PCR Assays for the fast, specific & sensitive detection of viral pathogens in primary human stem cell lines. Validation data of the individual steps of the isolation & detection workflow will be presented. |
|
17:45 |
Close of Day 2 |
Day 3 - Wednesday 3rd September 2008
Business Track
|
09:25 |
Regulations, Intellectual Property and Commercialization
Chair: Enal Razvi, Biotechnology Analyst, Select Biosciences |
|
09:30 |
Building an hES Cell Screening Capability: Fast Track to Cell Production
Fergus McKenzie, Programme Manager, ITI Life Sciences |
|
10:00 |
Terms of Engagement: Knowledge Transfer Between Industry and Academia
Jolyon White, Technnology Consultant, London Technology Network
LTN is a very active technology brokerage. In the last 3 years (2004 to 2007) the network has facilitated 840 deals worth over £35M. Using case studies from the company’s own activity in this field Jolyon will illustrate: - where the deal begins, the drivers for the relationship, the barriers to completion of the deal, the value of the relationship in the valorisation of the deal, that there is a role for a third party broker, deal maker or facilitator? |
|
10:30 |
Coffee and Networking |
|
11:30 |
Keynote Presentation
Creating a New Stem Cell Action Agenda
Bernard Siegel, Executive Director, Genetics Policy Institute
The election of a new U.S. president and new research breakthroughs will not end the need for stem cell advocacy. Daunting roadblocks exist and contentious policy and legal battles remain unresolved. U.S. biopolitics will continue to impact the future of regenerative medicine in a significant way. In order to meet the challenges ahead, it is imperative that the stakeholders adopt a new stem cell action agenda. |
|
12:00 |
Moving Towards Becoming a Product-based Company
Johan Hyllner, Director, Cellartis |
|
12:30 |
Lunch and Networking |
|
13:25 |
Stem Cell Patentability
Chair: Dr Fergus McKenzie, ITI Life Sciences |
|
13:30 |
Patentability of Embroynic Stem Cells
Philippa Montgomerie, Associate, DLA Piper Scotland LLP |
|
14:00 |
Coffee and Networking |
|
14:30 |
Tissue Engineered Products: Conditions for a Supportive Regulatory Environment
Laure Brevignon-Dodin, Research Associate, University of Cambridge
Regulatory differences and market fragmentation across member states have hampered the development of the tissue engineering industry in the EU. |
|
15:00 |
IP Update: Patentability of Stem Cell Inventions in Europe
Nick Bassil, Patent Attorney, Kilburn and Strode
The IP landscape is a changeable and a potentially complex field, especially in relation to inventions in the field of stem cell technology. However, it need not be and there are simple points to understand which enable a clear path to be followed. The IP situation in Europe is under review and whatever the outcome of this process, interested parties need to be ready to adapt business strategies accordingly. Nick's presentation will focus on successful, cost-effective patenting strategies under the current law and with a view to the outcome of the review in Europe.
|
|
15:30 |
Panel Discussion |
|
16:00 |
Close of Conference | |